The Targetable Kinase PIM1 Drives ALK Inhibitor Resistance in High-Risk Neuroblastoma Independent of MYCN Status

Nature Communications - United Kingdom
doi 10.1038/s41467-019-13315-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma in Vivo

Molecular Cancer Therapeutics
Cancer ResearchOncology
2011English

Impact of MYCN Status on Response of High-Risk Neuroblastoma to Neoadjuvant Chemotherapy

Journal of Pediatric Surgery
MedicineChild HealthSurgeryPediatricsPerinatology
2020English

The ALK Inhibitor PF-06463922 Is Effective as a Single Agent in Neuroblastoma Driven by Expression of ALK and MYCN

DMM Disease Models and Mechanisms
ImmunologyMolecular BiologyBiochemistryMicrobiology NeuroscienceMedicineGenetics
2016English

MYCN Controls an Alternative RNA Splicing Program in High-Risk Metastatic Neuroblastoma

Cancer Letters
Cancer ResearchOncology
2016English

PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells

Cancer Research
Cancer ResearchOncology
2016English

Aberrant Activation of ALK Kinase by a Novel Truncated Form ALK Protein in Neuroblastoma

Oncogene
Cancer ResearchGeneticsMolecular Biology
2012English

Inhibition of Autophagy Potentiates the Efficacy of Gli Inhibitor GANT-61 in MYCN-amplified Neuroblastoma Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2014English

Aurora B Kinase Is a Potent and Selective Target in MYCN-driven Neuroblastoma

Oncotarget
Oncology
2015English

Ataxia-Telangiectasia Mutated (ATM) Silencing Promotes Neuroblastoma Progression Through a MYCN Independent Mechanism

Oncotarget
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy